BGEN doesn't own any assets - if so post the patents.
From BioClonetics Immunotherapeutics
INTELLECTUAL PROPERTY
The Company protects its technology through an aggressive strategy to cover its intellectual property. Such intellectual property includes:
PROPRIETARY CELL LINE PRODUCING CLONE 3
- The Company’s Clone 3 cell line, that produces fully human monoclonal
antibodies (mAbs) that specifically target and neutralize the HIV-1 virus, is
proprietary to the Company.
INTELLECTUAL PROPERTY PORTFOLIO
- Pending patent coverage on the recombinant of the Clone 3 antibody. This form of the Clone 3 antibody is prepared using the known amino acid sequence of the Antibody in conjunction with a high producing CHO cell line for generating recombinant
material that would ultimately be used in patient application.
- Pendintg Patent coverage of small molecules (mini-peptides) for commercial use derived from the structure of the Clone 3 antibody for interrupting and preventing binding between the HIV virus and the human CD4+ cell.
- Coverage is directed to blocking peptides that bind to and neutralize the HIV virus, and
- Competitive peptides that bind to the target CD4+ cells at the point of virus access into the human cell to prevent infection.
When you file a provisional patent - which excludes any prior art - it is a 12 month placeholder and you are allowed to use the term patent pending.
Here is an example:
Patent number: 6083504
InventorJoseph P. Cotropia
Assignee BIOCLONETICS IMMUNOTHERAPEUTICS Inc
Status: Expired
Then we have Patent Number 5777074
InventorJoseph P. Cotropia
Assignee BIOCLONETICS IMMUNOTHERAPEUTICS Inc
Status: Expired
US6008044A - and it has expired.
BIOCLONETICS Immunotherapeutics is a empty shell without any IP.
IG
The First Casualty of Emotion is Reason.
